Patrick Grogan
Medical Oncology · Tampa, FLNPI 1326492430
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,600 of the $3,106 with a category attached, or 83.7%. Novocure Inc. accounts for 89.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $2,846 and has fallen 97.9% since, to $59 in 2025. That places this record below the midpoint for medical oncology clinicians in FL, where the typical reported total is $8,890.
Across 10 payments — averaging $310.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$3K
- Lilly USA, LLC$201
- Lundbeck LLC$59
- SK Life Science, Inc.$33
- Eisai Inc.$21
Across 30 payments — averaging $6066.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novocure GmbH$71K
- Novocure Inc.$59K
- Jazz Pharmaceuticals Inc.$52K
What the payments were for
- Speaking & faculty fees$2,60084%
- Food & beverage$30510%
- Education$2016%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 4 | $2,792 |
| Lilly USA, LLC | 2 | $201 |
| Lundbeck LLC | 2 | $59 |
| SK Life Science, Inc. | 1 | $33 |
| Eisai Inc. | 1 | $21 |
How this compares
$3,106 in reported general payments places this provider in the 30th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 16 | $22,147 |
| EliquisApixaban | 15 | $9,902 |
| Dexamethasone | 149 | $3,068 |
| Ondansetron Hcl | 68 | $1,806 |
| Levetiracetam | 65 | $1,377 |
| Lacosamide | 27 | $1,333 |
| Acyclovir | 33 | $549 |
| Pantoprazole Sodium | 52 | $469 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 45 | $348 |
| Omeprazole | 16 | $120 |
| Trazodone Hcl | 27 | $116 |
| Fluoxetine Hcl | 11 | $77 |
| Famotidine | 14 | $67 |
| Lorazepam | 15 | $20 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.